Minerva Neurosciences, Inc.
NERV · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.08 | 0.01 | -0.00 |
| FCF Yield | -46,964,117.57% | 0.00% | -30.75% | -71,174,275.16% |
| EV / EBITDA | -17.74 | -14.81 | -12.98 | 2.38 |
| Quality | ||||
| ROIC | -12.10% | -12.65% | -13.18% | -11.39% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 1.06 | 0.63 | 1.21 | -0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 100.00% | -365,320,255.46% |
| Safety | ||||
| Net Debt / EBITDA | -13.74 | -11.38 | -9.05 | 1.49 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -59,346.99 | -42,318.25 | -6,855.18 | -8,862.10 |